Dr. Eric Vallieres, MD
NPI: 1881750743
Total Payments
$218,879
2024 Payments
$25,111
Companies
27
Transactions
219
Medicare Patients
410
Medicare Billing
$57,349
Payment Breakdown by Category
Other$97,749 (44.7%)
Consulting$88,796 (40.6%)
Travel$16,303 (7.4%)
Research$10,549 (4.8%)
Food & Beverage$5,483 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $97,749 | 43 | 44.7% |
| Consulting Fee | $88,796 | 41 | 40.6% |
| Travel and Lodging | $16,303 | 52 | 7.4% |
| Unspecified | $10,549 | 13 | 4.8% |
| Food and Beverage | $5,483 | 70 | 2.5% |
Payments by Type
General
$208,330
206 transactions
Research
$10,549
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $124,619 | 108 | $0 (2024) |
| Gyrus ACMI, Inc. | $23,080 | 14 | $0 (2021) |
| Merck Sharp & Dohme LLC | $16,388 | 16 | $0 (2024) |
| Spiration, Inc. | $14,963 | 9 | $0 (2020) |
| F. Hoffmann-La Roche AG | $11,938 | 16 | $0 (2024) |
| Medical Device Business Services, Inc. | $9,755 | 8 | $0 (2017) |
| AbbVie, Inc. | $5,540 | 8 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $3,133 | 6 | $0 (2022) |
| Regeneron Pharmaceuticals, Inc. | $3,014 | 3 | $0 (2017) |
| AstraZeneca UK Limited | $2,925 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $25,111 | 29 | Merck Sharp & Dohme LLC ($16,388) |
| 2023 | $41,099 | 39 | AstraZeneca Pharmaceuticals LP ($34,357) |
| 2022 | $22,365 | 28 | AstraZeneca Pharmaceuticals LP ($17,369) |
| 2021 | $45,249 | 32 | AstraZeneca Pharmaceuticals LP ($24,650) |
| 2020 | $27,155 | 26 | AstraZeneca Pharmaceuticals LP ($22,763) |
| 2019 | $21,456 | 21 | AstraZeneca Pharmaceuticals LP ($16,542) |
| 2018 | $8,806 | 9 | Spiration, Inc. ($5,696) |
| 2017 | $27,639 | 35 | Medical Device Business Services, Inc. ($9,755) |
All Payment Transactions
219 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $589.68 | Research |
| Study: PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC • Category: BioOncology | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $532.89 | Research |
| Study: IMpower010 5-y subgroup analysis and relapse patterns: Phase 3 study of atezolizumab vs BSC in stage II-IIIA NSCLC • Category: BioOncology | ||||||
| 10/25/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $647.44 | Research |
| Study: PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC • Category: BioOncology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $589.68 | Research |
| Study: PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC • Category: BioOncology | ||||||
| 09/25/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $250.00 | General |
| Category: Oncology | ||||||
| 09/08/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $88.54 | General |
| 09/07/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $75.51 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $1,351.97 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $304.20 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $56.79 | General |
| Category: ONCOLOGY | ||||||
| 06/18/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $121.50 | General |
| 05/16/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $131.57 | General |
| 04/25/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,300.00 | General |
| Category: Oncology | ||||||
| 04/18/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | In-kind items and services | $854.16 | General |
| Category: Oncology | ||||||
| 04/18/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $124.03 | General |
| Category: Oncology | ||||||
| 04/10/2024 | Zimmer Biomet Holdings, Inc. | AdvantageRib (Device) | Food and Beverage | In-kind items and services | $193.39 | General |
| Category: CMF & Thoracic | ||||||
| 04/03/2024 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| 04/01/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 03/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $136.84 | General |
| Category: ONCOLOGY | ||||||
| 03/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $59.99 | General |
| Category: ONCOLOGY | ||||||
| 03/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $54.99 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | F. Hoffmann-La Roche AG | $8,128 | 10 |
| A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER | F. Hoffmann-La Roche AG | $1,888 | 2 |
| IMpower010 5-y subgroup analysis and relapse patterns: Phase 3 study of atezolizumab vs BSC in stage II-IIIA NSCLC | F. Hoffmann-La Roche AG | $532.89 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 110 | 133 | $71,773 | $21,429 |
| 2022 | 3 | 66 | 105 | $24,501 | $7,779 |
| 2021 | 5 | 110 | 116 | $58,896 | $14,229 |
| 2020 | 6 | 124 | 160 | $59,399 | $13,911 |
Total Patients
410
Total Services
514
Medicare Billing
$57,349
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 32666 | Initial removal of wedge of lung tissue using an endoscope | Facility | 2023 | 13 | 13 | $34,700 | $9,055 | 26.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $16,065 | $5,191 | 32.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 42 | 53 | $11,713 | $3,728 | 31.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 14 | 15 | $6,570 | $2,390 | 36.4% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 14 | 25 | $2,725 | $1,065 | 39.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 37 | 47 | $9,917 | $3,305 | 33.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $10,115 | $3,128 | 30.9% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 12 | 41 | $4,469 | $1,347 | 30.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 34 | 34 | $20,230 | $6,578 | 32.5% |
| 39402 | Examination of chest using an endoscope with lymph node biopsy | Facility | 2021 | 12 | 12 | $12,204 | $2,433 | 19.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 28 | 34 | $7,174 | $2,311 | 32.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 17 | 17 | $5,304 | $1,814 | 34.2% |
| 31622 | Diagnostic examination of lung airways using an endoscope | Facility | 2021 | 19 | 19 | $13,984 | $1,094 | 7.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 24 | 24 | $13,608 | $4,313 | 31.7% |
| 39402 | Examination of chest using an endoscope with lymph node biopsy | Facility | 2020 | 14 | 14 | $14,238 | $3,491 | 24.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 24 | 25 | $7,425 | $2,034 | 27.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 31 | 32 | $6,432 | $1,799 | 28.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 14 | 48 | $5,184 | $1,286 | 24.8% |
| 31622 | Diagnostic examination of lung airways using an endoscope | Facility | 2020 | 17 | 17 | $12,512 | $988.03 | 7.9% |
About Dr. Eric Vallieres, MD
Dr. Eric Vallieres, MD is a Thoracic Surgery (Cardiothoracic Vascular Surgery) healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1881750743.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Vallieres, MD has received a total of $218,879 in payments from pharmaceutical and medical device companies, with $25,111 received in 2024. These payments were reported across 219 transactions from 27 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($97,749).
As a Medicare-enrolled provider, Vallieres has provided services to 410 Medicare beneficiaries, totaling 514 services with total Medicare billing of $57,349. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Thoracic Surgery (Cardiothoracic Vascular Surgery)
- Location Seattle, WA
- Active Since 12/28/2006
- Last Updated 04/23/2021
- Taxonomy Code 208G00000X
- Entity Type Individual
- NPI Number 1881750743
Products in Payments
- TAGRISSO (Drug) $90,661
- IMFINZI (Drug) $26,853
- Spiration Valve System (Device) $13,125
- KEYTRUDA (Biological) $11,968
- MATRIXRIB (Device) $9,894
- Tecentriq (Biological) $8,661
- TECENTRIQ (Biological) $3,277
- IMFINZI (Biological) $1,026
- Olympus Respiratory Accessories (Device) $918.75
- Olympus Respiratory Devices (Device) $918.75
- ENDOFLIP (Device) $335.40
- Da Vinci Surgical System (Device) $299.78
- AdvantageRib (Device) $193.39
- Avastin (Biological) $154.13
- ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2) (Device) $145.79
- GENERAL PULMONARY (Device) $142.93
- ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM (Device) $110.54
- ON-Q PUMP AND ACCESSORIES (Device) $106.69
- Product Portfolio (Device) $97.61
- Rib Fix Blu (Device) $61.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Thoracic Surgery (Cardiothoracic Vascular Surgery) Doctors in Seattle
Dr. Glenn Barnhart, Md, MD
Thoracic Surgery (Cardiothoracic Vascular Surgery) — Payments: $608,190
Thoracic Surgery (Cardiothoracic Vascular Surgery) $608,190
Dr. Eric Lehr, M.d., Phd, M.D., PHD
Thoracic Surgery (Cardiothoracic Vascular Surgery) — Payments: $88,223
Thoracic Surgery (Cardiothoracic Vascular Surgery) $88,223
Dr. Paul Hayes, Md, MD
Thoracic Surgery (Cardiothoracic Vascular Surgery) — Payments: $70,058
Thoracic Surgery (Cardiothoracic Vascular Surgery) $70,058
Jonathan Chen
Thoracic Surgery (Cardiothoracic Vascular Surgery) — Payments: $31,347
Thoracic Surgery (Cardiothoracic Vascular Surgery) $31,347
Douglas Wood
Thoracic Surgery (Cardiothoracic Vascular Surgery) — Payments: $23,972
Thoracic Surgery (Cardiothoracic Vascular Surgery) $23,972
Michael Mulligan, Md, MD
Thoracic Surgery (Cardiothoracic Vascular Surgery) — Payments: $21,339
Thoracic Surgery (Cardiothoracic Vascular Surgery) $21,339